Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner

Cell Death and Disease

Volumn 6, Issue 5, 2015, Pages

  Werthmoller N ^a   Frey, B ^a   Wunderlich, R ^a   Fietkau, R ^a   Gaipl, U S ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APYRASE; CARBOBENZOXY VALYLALANYLASPARTIC ACID [O METHYL] FLUOROMETHYLKETONE; CASPASE INHIBITOR; CD86 ANTIGEN; DACARBAZINE; GAMMA INTERFERON; HIGH MOBILITY GROUP B1 PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; UNCLASSIFIED DRUG; BENZYLOXYCARBONYLVALYL-ALANYL-ASPARTYL FLUOROMETHYL KETONE; CD86 PROTEIN, MOUSE; HLA ANTIGEN CLASS 2; HMGB1 PROTEIN, MOUSE; HOMEODOMAIN PROTEIN; MYD88 PROTEIN, MOUSE; MYELOID DIFFERENTIATION FACTOR 88; PEPTIDE CHLOROMETHYL KETONE; RAG-1 PROTEIN; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CELL DEATH; CELL INFILTRATION; CHEMORADIOTHERAPY; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HYPERTHERMIA; IMMUNOGENICITY; IMMUNOMODULATION; IN VIVO STUDY; INCUBATION TIME; LYMPH NODE; MACROPHAGE; MELANOMA B16; MELANOMA CELL; MOUSE; NECROPTOSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SUPERNATANT; T LYMPHOCYTE; TUMOR IMMUNITY; UPREGULATION; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IONIZING RADIATION; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; METABOLISM; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PERITONEUM MACROPHAGE; RADIATION RESPONSE; SECRETION (PROCESS); THERMOTHERAPY; TUMOR CELL LINE;

AMINO ACID CHLOROMETHYL KETONES; ANIMALS; ANTIGENS, CD86; APOPTOSIS; APYRASE; CASPASE INHIBITORS; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; DACARBAZINE; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HMGB1 PROTEIN; HOMEODOMAIN PROTEINS; HYPERTHERMIA, INDUCED; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MACROPHAGES, PERITONEAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; RADIATION, IONIZING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84957310840     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2015.129     Document Type: Article

References (64)

1. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-998.
2. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
3. Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 2008; 22: 1064-1070.
4. Rubner Y, Wunderlich R, Ruhle PF, Kulzer L, Werthmoller N, Frey B et al. How does ionizing irradiation contribute to the induction of anti-tumor immunity? Front Oncol 2012; 2: 75.
5. Zitvogel L, Casares N, Pequignot MO, Chaput N, Albert ML, Kroemer G. Immune response against dying tumor cells. Adv Immunol 2004; 84: 131-179.
6. Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature 1997; 390: 350-351.
7. Gaipl US, Sheriff A, Franz S, Munoz LE, Voll RE, Kalden JR et al. Inefficient clearance of dying cells and autoreactivity. Curr Top Microbiol Immunol 2006; 305: 161-176.
8. Schulze C, Munoz LE, Franz S, Sarter K, Chaurio RA, Gaipl US et al. Clearance deficiency- a potential link between infections and autoimmunity. Autoimmun Rev 2008; 8: 5-8.
9. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47-59.
10. Ullrich E, Bonmort M, Mignot G, Kroemer G, Zitvogel L. Tumor stress, cell death and the ensuing immune response. Cell Death Differ 2008; 15: 21-28.
11. Fucikova J, Kralikova P, Fialova A, Brtnicky T, Rob L, Bartunkova J et al. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71: 4821-4833.
12. Castiglioni A, Canti V, Rovere-Querini P, Manfredi AA. High-mobility group box 1 (HMGB1) as a master regulator of innate immunity. Cell Tissue Res 2011; 343: 189-199.
13. Yang D, Chen Q, Yang H, Tracey KJ, Bustin M, Oppenheim JJ. High mobility group box-1 protein induces the migration and activation of human dendritic cells and acts as an alarmin. J Leukoc Biol 2007; 81: 59-66.
14. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A et al. Involvement of tolllike receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004; 279: 7370-7377.
15. Dumitriu IE, Bianchi ME, Bacci M, Manfredi AA, Rovere-Querini P. The secretion of HMGB1 is required for the migration of maturing dendritic cells. J Leukoc Biol 2007; 81: 84-91.
16. Krysko O, Love Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis 2013; 4: e631.
17. Aymeric L, Apetoh L, Ghiringhelli F, Tesniere A, Martins I, Kroemer G et al. Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. Cancer Res 2010; 70: 855-858.
18. Ma Y, Shurin GV, Peiyuan Z, Shurin MR. Dendritic cells in the cancer microenvironment. J Cancer 2013; 4: 36-44.
19. Moyer JS, Li J, Wei S, Teitz-Tennenbaum S, Chang AE. Intratumoral dendritic cells and chemoradiation for the treatment of murine squamous cell carcinoma. J Immunother 2008; 31: 885-895.
20. Teitz-Tennenbaum S, Li Q, Okuyama R, Davis MA, Sun R, Whitfield J et al. Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. J Immunother 2008; 31: 345-358.
21. Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, Gui J et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother 2011; 34: 382-389.
22. Krawczyk PM, Eppink B, Essers J, Stap J, Rodermond H, Odijk H et al. Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition. Proc Natl Acad Sci USA 2011; 108: 9851-9856.
23. Frey B, Weiss EM, Rubner Y, Wunderlich R, Ott OJ, Sauer R et al. Old and new facts about hyperthermia-induced modulations of the immune system. Int J Hyperthermia 2012; 28: 528-542.
24. Anvekar RA, Asciolla JJ, Lopez-Rivera E, Floros KV, Izadmehr S, Elkholi R et al. Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. Cell Death Dis 2012; 3: e420.
25. Zitvogel L, Kroemer G. OncoImmunology: a new journal at the frontier between oncology and immunology. Oncoimmunology 2012; 1: 1-2.
26. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol 2010; 11: 700-714.
27. Vanden Berghe T, Vanlangenakker N, Parthoens E, Deckers W, Devos M, Festjens N et al. Necroptosis, necrosis and secondary necrosis converge on similar cellular disintegration features. Cell Death Differ 2010; 17: 922-930.
28. Vercammen D, Beyaert R, Denecker G, Goossens V, Van Loo G, Declercq W et al. Inhibition of caspases increases the sensitivity of L929 cells to necrosis mediated by tumor necrosis factor. J Exp Med 1998; 187: 1477-1485.
29. Christofferson DE, Yuan J. Necroptosis as an alternative form of programmed cell death. Curr Opin Cell Biol 2010; 22: 263-268.
30. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003; 348: 1365-1375.
31. Moretti L, Kim KW, Jung DK, Willey CD, Lu B, Hwang M et al. Radiosensitization of solid tumors by Z-VAD, a pan-caspase inhibitor. Mol Cancer Ther 2009; 8: 1270-1279.
32. Ko SH, Ueno T, Yoshimoto Y, Yoo JS, Abdel-Wahab OI, Abdel-Wahab Z et al. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. Clin Cancer Res 2006; 12: 289-297.
33. Los M, Gibson SB. Apoptotic Pathways as Targets for Novel Therapies in Cancer and Other Diseases. Springer: US, 2005.
34. Triantopoulou S, Efstathopoulos E, Platoni K, Uzunoglou N, Kelekis N, Kouloulias V. Radiotherapy in conjunction with superficial and intracavitary hyperthermia for the treatment of solid tumors: survival and thermal parameters. Clin Transl Oncol 2012; 21: 21.
35. Zitvogel L, Apetoh L, Ghiringhelli F, André F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest 2008; 118: 1991-2001.
36. Schnorrer P, Behrens GM, Wilson NS, Pooley JL, Smith CM, El-Sukkari D et al. The dominant role of CD8+ dendritic cells in cross-presentation is not dictated by antigen capture. Proc Natl Acad Sci USA 2006; 103: 10729-10734.
37. Khan N, Khan MK, Almasan A, Singh AD, Macklis R. The evolving role of radiation therapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys 2011; 80: 645-654.
38. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, Arcangeli G, Dahl O, Mella O et al. Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12: 3-20.
39. Wolter KG, Verhaegen M, Fernandez Y, Nikolovska-Coleska Z, Riblett M, de la Vega CM et al. Therapeutic window for melanoma treatment provided by selective effects of the proteasome on Bcl-2 proteins. Cell Death Differ 2007; 14: 1605-1616.
40. Jendrossek V. The intrinsic apoptosis pathways as a target in anticancer therapy. Curr Pharm Biotechnol 2012; 13: 1426-1438.
41. Iwata A, Morgan-Stevenson V, Schwartz B, Liu L, Tupper J, Zhu X et al. Extracellular BCL2 proteins are danger-associated molecular patterns that reduce tissue damage in murine models of ischemia-reperfusion injury. PloS One 2010; 5: e9103.
42. Shiffman ML, Pockros P, McHutchison JG, Schiff ER, Morris M, Burgess G. Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor - a randomized placebocontrolled study in patients with chronic hepatitis C. Aliment Pharmacol Ther 2010; 31: 969-978.
43. Palumbo S, Comincini S. Autophagy and ionizing radiation in tumors: the "survive or not survive" dilemma. J Cell Physiol 2013; 228: 1-8.
44. Tapia IJ, Aris M, Arriaga JM, Blanco PA, Mazzobre F, Vega J et al. Development of a novel methodology for cryopreservation of melanoma cells applied to CSF470 therapeutic vaccine. Cryobiology 2013; 67: 163-169.
45. Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK et al. Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 2003; 113: 717-730.
46. Wu YT, Tan HL, Huang Q, Sun XJ, Zhu X, Shen HM. zVAD-induced necroptosis in L929 cells depends on autocrine production of TNFalpha mediated by the PKC-MAPKs-AP-1 pathway. Cell Death Differ 2011; 18: 26-37.
47. Murphy JM, Czabotar PE, Hildebrand JM, Lucet IS, Zhang JG, Alvarez-Diaz S et al. The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 2013; 39: 443-453.
48. Weiss EM, Wunderlich R, Ebel N, Rubner Y, Schlucker E, Meyer-Pittroff R et al. Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Front Oncol 2012; 2: 132.
49. Pisetsky DS. The translocation of nuclear molecules during inflammation and cell death. Antioxidants & redox signaling 2014; 20: 1117-1125.
50. Vezzoli M, Castellani P, Corna G, Castiglioni A, Bosurgi L, Monno A et al. High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. Antioxid Redox Signal 2011; 15: 2161-2174.
51. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006; 290: C917-C924.
52. Akira S, Takeda K. Functions of toll-like receptors: lessons from KO mice. C R Biol 2004; 327: 581-589.
53. Laliberte JF, St-Jean P, Beaudoin AR. Kinetic effects of Ca2+ and Mg2+ on ATP hydrolysis by the purified ATP diphosphohydrolase. J Biol Chem 1982; 257: 3869-3874.
54. Cauwels A, Rogge E, Vandendriessche B, Shiva S, Brouckaert P. Extracellular ATP drives systemic inflammation, tissue damage and mortality. Cell Death Dis 2014; 5: e1102.
55. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem 1998; 273: 32608-32613.
56. Umansky V, Shevchenko I, Bazhin AV, Utikal J. Extracellular adenosine metabolism in immune cells in melanoma. Cancer Immunol Immunother 2014; 63: 1073-1080.
57. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med 2000; 192: 1685-1696.
58. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004; 58: 862-870.
59. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013; 1: 365-372.
60. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366: 925-931.
61. Schildkopf P, Frey B, Ott OJ, Rubner Y, Multhoff G, Sauer R et al. Radiation combined with hyperthermia induces HSP70-dependent maturation of dendritic cells and release of proinflammatory cytokines by dendritic cells and macrophages. Radiother Oncol 2011; 101: 109-115.
62. Schleicher U, Bogdan C. Generation, culture and flow-cytometric characterization of primary mouse macrophages. Methods Mol Biol 2009; 531: 203-224.
63. Lutz MB, Kukutsch N, Ogilvie AL, Rossner S, Koch F, Romani N et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods 1999; 223: 77-92.
64. Geran RI, Greenberg NH, Macdonald MM, Abbott BJ. Modified protocol for the testing of new synthetics in the L1210 lymphoid leukemia murine model in the DR&D program, DCT, NCI. Natl Cancer Inst Monogr 1977: 151-153.